• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    68 Biggest Movers From Yesterday

    4/5/22 6:37:16 AM ET
    $AERC
    $ARRY
    $ARTW
    $ATER
    Environmental Services
    Utilities
    Miscellaneous manufacturing industries
    Consumer Discretionary
    Get the next $AERC alert in real time by email

    Gainers

    • GBS Inc. (NASDAQ:GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation.
    • Aterian, Inc. (NASDAQ:ATER) shares surged 46.8% to close at $3.42 on Monday. Aterian said Cynthia Williams has joined the Company's Board of Directors.
    • Protalix BioTherapeutics, Inc. (NYSE:PLX) gained 41.9% to settle at $1.49. Protalix BioTherapeutics and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., announced topline data from the BALANCE Phase 3 trial evaluating pegunigalsidase alfa (PRX–102) for Fabry disease.
    • IO Biotech, Inc. (NASDAQ:IOBT) rose 33.2% to settle at $7.55. IO Biotech recently reported cash and equivalents of $211.5 million as of Dec. 31.
    • VirnetX Holding Corp (NYSE:VHC) jumped 31.3% to close at $2.18.
    • Dingdong (Cayman) Limited (NYSE:DDL) surged 28.8% to close at $4.70.
    • BRC Inc. (NYSE:BRCC) gained 28.7% to close at $28.28.
    • Cognition Therapeutics, Inc. (NASDAQ:CGTX) jumped 28.1% to close at $3.33. Cognition Therapeutics recently posted FY21 loss of $3.13 per share.
    • Twitter, Inc. (NYSE:TWTR) shares surged 27.1% to close at $49.97 after Tesla CEO Elon Musk disclosed a 9.2% passive stake in the social media company.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) gained 26.4% to close at $0.90. Esports Entertainment, last month, named Damian Mathews as Finance Chief.
    • Jumia Technologies AG (NASDAQ:JMIA) rose 24.7% to close at $11.82 after the company announced it would make its last mile logistics capabilities available to UPS.
    • Lilium N.V. (NASDAQ:LILM) jumped 24.6% to close at $4.86 after the company announced it has begun flight testing at the ATLAS Flight Test Center in Spain.
    • Poema Global Holdings Corp. (NASDAQ:PPGH) rose 23.7% to close at $12.74 following the completion of its business combination with Gogoro.
    • Oragenics, Inc. (NYSE:OGEN) gained 23.6% to close at $0.4170. Oragenics Director Fred Telling acquired a total of 183,838 shares at an average price of $0.36.
    • Yatsen Holding Limited (NYSE:YSG) jumped 23.1% to close at $0.8432.
    • IN8bio, Inc. (NASDAQ:INAB) jumped 22.4% to close at $4.21.
    • Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) gained 22.3% to settle at $2.25.
    • Precipio, Inc. (NASDAQ:PRPO) surged 21.7% to close at $1.68. The company released Q4 results.
    • Liquid Media Group Ltd. (NASDAQ:YVR) gained 21.4% to close at $0.9681.
    • Singularity Future Technology Ltd. (NASDAQ:SGLY) climbed 21.1% to close at $14.97.
    • Red Cat Holdings, Inc. (NASDAQ:RCAT) surged 21% to close at $2.36 after the company announced a drone order for use in Ukraine.
    • Qutoutiao Inc. (NASDAQ:QTT) jumped 20.8% to close at $1.83.
    • LianBio (NASDAQ:LIAN) gained 20.6% to close at $4.50.
    • Tempest Therapeutics, Inc. (NASDAQ:TPST) rose 20.3% to close at $3.85. Tempest Therapeutics posted FY21 loss of $7.47 per share.
    • Futu Holdings Limited (NASDAQ:FUTU) climbed 19.5% to close at $41.35.
    • Regional Health Properties, Inc. (NYSE:RHE) gained 19.4% to close at $4.12.
    • Nuvectis Pharma, Inc. (NASDAQ:NVCT) gained 19.1% to close at $8.36.
    • Xcel Brands, Inc. (NASDAQ:XELB) surged 18.6% to close at $1.66 after the company issued FY21 sales guidance above analyst estimates.
    • Gracell Biotechnologies Inc. (NASDAQ:GRCL) gained 18.3% to close at $2.65 after BTIG initiated coverage on the stock with a Buy rating and a $18 price target.
    • Nuvve Holding Corp. (NASDAQ:NVVE) climbed 17.7% to close at $8.25. Nuvve Holding recently reported Q4 financial results.
    • iQIYI, Inc. (NASDAQ:IQ) jumped 16.7% to settle at $5.58.
    • Bilibili Inc. (NASDAQ:BILI) rose 16.6% to settle at $32.19 after surging 8% on Friday.
    • Perion Network Ltd. (NASDAQ:PERI) gained 15.9% to close at $26.51 after the company reported better-than-expected Q1 financial results.
    • Full Truck Alliance Co. Ltd. (NYSE:YMM) gained 15.8% to close at $8.30.
    • Ollie's Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) climbed 15.7% to close at $49.56 after Wells Fargo upgraded the stock from Equal-Weight to Overweight and announced a $65 price target.
    • iHuman Inc. (NYSE:IH) jumped 15.6% to close at $2.43.
    • Pinduoduo Inc. (NASDAQ:PDD) climbed 15.6% to close at $49.30 following a potential rule change which would allow Chinese companies to share sensitive data with US regulators, thus lowering risk of delisting.
    • RCM Technologies, Inc. (NASDAQ:RCMT) climbed 15% to close at $12.59.
    • Biophytis SA (NASDAQ:BPTS) gained 14.7% to close at $2.57.
    • Inozyme Pharma, Inc. (NASDAQ:INZY) rose 14.1% to close at $4.30 as the company announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its Phase 1/2 trial of INZ-701 in ENPP1 Deficiency.
    • Borr Drilling Limited (NYSE:BORR) climbed 13.3% to close at $4.59.
    • The RealReal, Inc. (NASDAQ:REAL) gained 11.8% to close at $8.07.
    • SPI Energy Co., Ltd. (NASDAQ:SPI) climbed 11.6% to close at $3.17 after reporting record revenue of $162 million for 2021.
    • Context Therapeutics Inc. (NASDAQ:CNTX) shares jumped 10.8% to settle at $2.66 after jumping over 10% on Friday. Context Therapeutics recently posted FY21 net loss of $10.5 million.
    • Array Technologies, Inc. (NASDAQ:ARRY) gained 9% to close at $11.92 after the company announced it will supply advanced tracker technology for "the largest solar + storage project in the US."
    • Clovis Oncology, Inc. (NASDAQ:CLVS) gained 8.8% to close at $2.72.
    • TMC the metals company Inc. (NASDAQ:TMC) climbed 8.6% to close at $2.66.
    • Borqs Technologies, Inc. (NASDAQ:BRQS) gained 8.1% to settle at $0.2270. TDR Capital reported a new stake of 9.9% in Borqs Technologies.

     

    Don’t forget to check out our premarket coverage here .

    Losers

    • Curis, Inc. (NASDAQ:CRIS) shares fell 33.3% to close at $1.62 on Monday. The FDA has placed a partial clinical hold on Curis Inc's TakeAim Leukemia Phase 1/2a study in relapsed or refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    • Forge Global Holdings, Inc. (NYSE:FRGE) dipped 21.8% to close at $23.20.
    • GWG Holdings, Inc. (NASDAQ:GWGH) fell 21% to close at $4.22.
    • Snow Lake Resources Ltd. (NASDAQ:LITM) fell 19.3% to close at $8.10.
    • Art's-Way Manufacturing Co., Inc. (NASDAQ:ARTW) dipped 18.5% to close at $4.54. Art's Way Manufacturing announced an 8.9% year-over-year increase in agricultural products segment revenue for Q1.
    • Longeveron Inc. (NASDAQ:LGVN) dropped 17.7% to settle at $12.85. A leading medical journal published study of Longeveron's Phase 1 trial results for Alzheimer's disease.
    • Insignia Systems, Inc. (NASDAQ:ISIG) dropped 16.8% to settle at $10.56.
    • Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) declined 16.8% to close at $1.24. Clarus Therapeutics recently reported Q4 earnings results.
    • Weidai Ltd. (NYSE:WEI) fell 16.1% to close at $1.20 after jumping 29% on Friday.
    • Expion360 Inc. (NASDAQ:XPON) dipped 15.9% to close at $6.67. This new issue opened for trade on Friday of last week.
    • Yunhong CTI Ltd. (NASDAQ:CTIB) dropped 15.8% to close at $1.12.
    • AeroClean Technologies, Inc. (NASDAQ:AERC) fell 15.3% to close at $3.88. AeroClean Technologies recently posted a Q4 loss of $0.13 per share.
    • Iveda Solutions, Inc. (NASDAQ:IVDA) fell 14.3% to close at $3.23. Iveda reported pricing of $8.0 million public offering, uplisting to Nasdaq and reverse stock split.
    • Recruiter.com Group, Inc. (NASDAQ:RCRT) dipped 14.2% to settle at $2.12.
    • Vertex Energy, Inc. (NASDAQ:VTNR) dropped 12.5% to close at $8.67.
    • Matson, Inc. (NASDAQ:MATX) dipped 11.5% to close at $102.25.
    • NextDecade Corporation (NASDAQ:NEXT) fell 11.1% to close at $6.17. Credit Suisse recently downgraded NextDecade from Outperform to Neutral and raised the price target from $3 to $7.5.
    • Rail Vision Ltd. (NASDAQ:RVSN) declined 10.3% to close at $2.44 following Thursday's IPO.
    • Digital World Acquisition Corp. (NASDAQ:DWAC) fell 10% to settle at $56.94 amid Tesla CEO Elon Musk purchasing a 9.2% stake in competitor Twitter.
    • Sharps Compliance Corp. (NASDAQ:SMED) fell 5.9% to close at $5.40. Sharps Compliance named Pat Mulloy as CEO.
    Get the next $AERC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AERC
    $ARRY
    $ARTW
    $ATER

    CompanyDatePrice TargetRatingAnalyst
    Array Technologies Inc.
    $ARRY
    2/26/2026$9.00Buy → Hold
    Deutsche Bank
    Array Technologies Inc.
    $ARRY
    2/25/2026$19.00Neutral → Outperform
    BNP Paribas Exane
    NextDecade Corporation
    $NEXT
    2/6/2026$7.00Overweight
    CapitalOne
    Jumia Technologies AG
    $JMIA
    2/6/2026$18.00Overweight
    Cantor Fitzgerald
    Futu Holdings Limited
    $FUTU
    2/2/2026$213.39Neutral → Buy
    Goldman
    Array Technologies Inc.
    $ARRY
    1/28/2026$11.00Outperform → Neutral
    Robert W. Baird
    IO Biotech Inc.
    $IOBT
    1/26/2026$0.50Overweight → Neutral
    Piper Sandler
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $AERC
    $ARRY
    $ARTW
    $ATER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Array Tech downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Array Tech from Buy to Hold and set a new price target of $9.00

    2/26/26 7:10:22 AM ET
    $ARRY
    Miscellaneous manufacturing industries
    Consumer Discretionary

    Array Tech upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Array Tech from Neutral to Outperform and set a new price target of $19.00

    2/25/26 7:19:45 AM ET
    $ARRY
    Miscellaneous manufacturing industries
    Consumer Discretionary

    CapitalOne initiated coverage on NextDecade with a new price target

    CapitalOne initiated coverage of NextDecade with a rating of Overweight and set a new price target of $7.00

    2/6/26 8:35:07 AM ET
    $NEXT
    Oil & Gas Production
    Utilities

    $AERC
    $ARRY
    $ARTW
    $ATER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:22:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $488 worth of shares (25 units at $19.50), increasing direct ownership by 3% to 995 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:21:46 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $505 worth of shares (31 units at $16.30), increasing direct ownership by 3% to 970 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:19:49 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AERC
    $ARRY
    $ARTW
    $ATER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Full Truck Alliance Co. Ltd. to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Earnings Call Scheduled for 8:00 A.M. U.S. ET on March 12, 2026 GUIYANG, China, Feb. 27, 2026 /PRNewswire/ -- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE:YMM), a leading digital freight platform, today announced that it will release its fourth quarter and fiscal year 2025 unaudited financial results on Thursday, March 12, 2026, before the open of the U.S. markets. The Company's management will hold an earnings conference call at 8:00 A.M. U.S. Eastern Time on March 12, 2026 or 8:00 P.M. Beijing Time to discuss the financial results.For participants who wish to join the conference using dial-in numbers, please complete online registration using the link provided below prior to

    2/27/26 3:00:00 AM ET
    $YMM
    Computer Software: Prepackaged Software
    Technology

    The RealReal Announces Fourth Quarter and Full Year 2025 Results

    Company surpassed $2 billion in GMV, accelerated active buyer growth, and exceeded 2025 financial guidance SAN FRANCISCO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The RealReal, Inc. (NASDAQ:REAL)—the world's largest online marketplace for authenticated, resale luxury goods—today reported financial results for its fourth quarter and full year ended December 31, 2025. Fourth quarter 2025 gross merchandise value (GMV) and total revenue increased 22% and 18%, respectively, compared to the fourth quarter of 2024. Full year 2025 GMV and total revenue increased 16% and 15% respectively, compared to the full year for 2024. Fourth quarter Adjusted EBITDA was $22 million, or 11.3% of total revenue, which

    2/26/26 4:03:00 PM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    moomoo Serves as First Brokerage Platform for Retail Access to Figure Technology Solutions Inc.'s blockchain-native share offering

    JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- moomoo, a global investment and trading platform, today announced that it was the first U.S. brokerage firm to provide retail investor access to Figure Technology Solutions Inc.'s blockchain-native share offering. The offering represents the first SEC-registered public equity issued in blockchain-native form. The transaction reflects moomoo's continued focus on enabling retail participation in new issuance formats for public equity, rather than new asset classes, while maintaining compliance with applicable U.S. securities regulations. Customers participated using U.S. dollar buying power through their existing moomoo brokerage accounts

    2/26/26 12:00:00 PM ET
    $FUTU
    Investment Bankers/Brokers/Service
    Finance

    $AERC
    $ARRY
    $ARTW
    $ATER
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    12/22/22 4:37:40 AM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-11) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 06/10/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    6/13/22 2:20:18 PM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AERC
    $ARRY
    $ARTW
    $ATER
    SEC Filings

    View All

    SEC Form S-8 filed by The RealReal Inc.

    S-8 - TheRealReal, Inc. (0001573221) (Filer)

    2/27/26 4:38:57 PM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    Precipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Precipio, Inc. (0001043961) (Filer)

    2/27/26 4:31:06 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Context Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Context Therapeutics Inc. (0001842952) (Filer)

    2/27/26 4:11:01 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AERC
    $ARRY
    $ARTW
    $ATER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Farnsworth Joseph A.

    4 - Iveda Solutions, Inc. (0001397183) (Issuer)

    2/25/26 4:30:23 PM ET
    $IVDA
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Director Franco Alejandro

    4 - Iveda Solutions, Inc. (0001397183) (Issuer)

    2/25/26 4:30:25 PM ET
    $IVDA
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Chief Executive Officer Ly David H.

    4 - Iveda Solutions, Inc. (0001397183) (Issuer)

    2/25/26 4:30:24 PM ET
    $IVDA
    Computer Software: Prepackaged Software
    Technology

    $AERC
    $ARRY
    $ARTW
    $ATER
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

    Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications Protalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercialization CARMIEL, Israel and MARTINSRIED, Germany, Dec. 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, and Secarna Pharmaceuticals GmbH & Co. KG, a company re

    12/17/25 6:50:00 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Red Cat Announces Key Leadership Transitions

    SAN JUAN, Puerto Rico, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (NASDAQ:RCAT) ("Red Cat" or the "Company"), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, today announced two strategic leadership transitions designed to strengthen operational execution and financial performance as the Company accelerates growth. Christian Ericson, Red Cat's current Chief Financial Officer (CFO), has been promoted to the new role of Chief Operating Officer (COO). Ericson joined Red Cat in March 2025 as Chief Financial Officer and has played a pivotal role in advancing Red Cat's financial foundation and operational capabilities. In

    12/2/25 4:05:00 PM ET
    $RCAT
    Computer Software: Prepackaged Software
    Technology

    $AERC
    $ARRY
    $ARTW
    $ATER
    Financials

    Live finance-specific insights

    View All

    Full Truck Alliance Co. Ltd. to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Earnings Call Scheduled for 8:00 A.M. U.S. ET on March 12, 2026 GUIYANG, China, Feb. 27, 2026 /PRNewswire/ -- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE:YMM), a leading digital freight platform, today announced that it will release its fourth quarter and fiscal year 2025 unaudited financial results on Thursday, March 12, 2026, before the open of the U.S. markets. The Company's management will hold an earnings conference call at 8:00 A.M. U.S. Eastern Time on March 12, 2026 or 8:00 P.M. Beijing Time to discuss the financial results.For participants who wish to join the conference using dial-in numbers, please complete online registration using the link provided below prior to

    2/27/26 3:00:00 AM ET
    $YMM
    Computer Software: Prepackaged Software
    Technology

    The RealReal Announces Fourth Quarter and Full Year 2025 Results

    Company surpassed $2 billion in GMV, accelerated active buyer growth, and exceeded 2025 financial guidance SAN FRANCISCO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The RealReal, Inc. (NASDAQ:REAL)—the world's largest online marketplace for authenticated, resale luxury goods—today reported financial results for its fourth quarter and full year ended December 31, 2025. Fourth quarter 2025 gross merchandise value (GMV) and total revenue increased 22% and 18%, respectively, compared to the fourth quarter of 2024. Full year 2025 GMV and total revenue increased 16% and 15% respectively, compared to the full year for 2024. Fourth quarter Adjusted EBITDA was $22 million, or 11.3% of total revenue, which

    2/26/26 4:03:00 PM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    Ollie's Bargain Outlet Holdings, Inc. Announces Fourth Quarter and Fiscal Year 2025 Earnings Release Date and Conference Call Information

    HARRISBURG, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ollie's Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) (the "Company") today announced that it will report its financial results for the fourth quarter and fiscal year 2025 before the market opens on Thursday, March 12, 2026. Eric van der Valk, President and Chief Executive Officer, and Robert Helm, Executive Vice President and Chief Financial Officer, will host a conference call with the investment community to discuss the financial results and answer questions at 8:30 a.m. Eastern Time on the same day. To access the live conference call, please pre-register here. Registrants will receive a confirmation with dial-in instructions. Interested

    2/26/26 8:00:00 AM ET
    $OLLI
    Department/Specialty Retail Stores
    Consumer Discretionary

    $AERC
    $ARRY
    $ARTW
    $ATER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Inozyme Pharma Inc.

    SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

    12/9/24 4:14:49 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Red Cat Holdings Inc.

    SC 13G/A - Red Cat Holdings, Inc. (0000748268) (Subject)

    12/6/24 4:32:04 PM ET
    $RCAT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by iQIYI Inc.

    SC 13D/A - iQIYI, Inc. (0001722608) (Subject)

    12/4/24 8:11:53 AM ET
    $IQ
    Consumer Electronics/Video Chains
    Consumer Discretionary